Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
INNOHEP vs ENOXAPARIN SODIUM
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Tinzaparin is a low molecular weight heparin that binds to antithrombin III, accelerating its inhibition of factor Xa and thrombin (factor IIa), thereby exerting anticoagulant effects.
Enoxaparin binds to antithrombin III (ATIII) via its pentasaccharide sequence, enhancing ATIII-mediated inhibition of factor Xa and, to a lesser extent, factor IIa (thrombin). It preferentially inhibits factor Xa over thrombin (anti-Xa:anti-IIa ratio ~3.6:1).
Treatment of acute symptomatic deep vein thrombosis (DVT) with or without pulmonary embolism (FDA-approved),Prophylaxis of venous thromboembolism in patients undergoing hip replacement surgery,Prophylaxis of venous thromboembolism in patients undergoing knee replacement surgery,Prophylaxis of venous thromboembolism in abdominal surgery
Prophylaxis of deep vein thrombosis (DVT) in abdominal or hip/knee replacement surgery,Prophylaxis of DVT in medical patients with acute illness and restricted mobility,Inpatient treatment of acute DVT with or without pulmonary embolism (PE) when administered with warfarin,Outpatient treatment of acute DVT without PE when administered with warfarin,Unstable angina and non-ST-segment elevation myocardial infarction (NSTEMI) when administered with aspirin,Acute ST-segment elevation myocardial infarction (STEMI) managed medically or with percutaneous coronary intervention (PCI)
Subcutaneous administration: 2500 IU anti-Xa (0.25 m L) once daily for low to moderate risk of thromboembolism; 3500 IU anti-Xa (0.35 m L) once daily for high risk. For treatment of deep vein thrombosis (DVT): 175 IU anti-Xa/kg body weight once daily by subcutaneous injection. Maximum dose: 17,500 IU per day.
1 mg/kg subcutaneous every 12 hours or 1.5 mg/kg subcutaneous once daily
Terminal half-life 3-4 hours; clinical context: once-daily dosing provides sustained anti-Xa activity.
4.5-7 hours after single subcutaneous dose; prolonged to 8-12 hours in renal impairment (Cr Cl <30 m L/min). Clinical context: maintains anti-Xa activity for 12 hours with once-daily dosing.
Tinzaparin is primarily metabolized in the liver via desulfation and depolymerization, with some involvement of renal excretion of lower molecular weight fragments.
Enoxaparin is partially metabolized in the liver via desulfation and depolymerization by heparanase and other enzymes. It has a complex pharmacokinetic profile with dose-dependent clearance; renal excretion accounts for elimination of active fragments and the unchanged drug.
Primarily renal; 40-50% of the dose excreted unchanged in urine; minor biliary/fecal elimination.
Renal (40-60% as unchanged drug via glomerular filtration and saturable tubular reabsorption). Biliary/fecal: negligible (<10%).
90% bound to antithrombin III.
80% bound to antithrombin III (low affinity to other plasma proteins).
0.15-0.25 L/kg; reflects limited extravascular distribution consistent with high protein binding.
0.04-0.06 L/kg (plasma volume distribution; low Vd indicates limited extravascular distribution).
Subcutaneous: 90-100%.
Subcutaneous: 90-92% (complete absorption).
For Cr Cl 30-50 m L/min: dose reduction by 25%; Cr Cl <30 m L/min: dose reduction by 50% and monitor anti-Xa activity. Alternative: avoid use if Cr Cl <30 m L/min.
Cr Cl < 30 m L/min: reduce dose to 1 mg/kg subcutaneous once daily
Child-Pugh A: no adjustment; Child-Pugh B: use with caution, consider dose reduction; Child-Pugh C: contraindicated.
No specific Child-Pugh based adjustment; use with caution in severe hepatic impairment due to increased bleeding risk
Not recommended for use in children due to lack of safety and efficacy data. Consider alternative low molecular weight heparins with established pediatric dosing.
Neonates and infants: 1.5 mg/kg subcutaneous every 12 hours; Children < 2 months: 1.5 mg/kg every 12 hours; Children ≥ 2 months: 1 mg/kg every 12 hours
Elderly patients (age ≥75 years) may have reduced renal function; dose should be based on renal function (see renal adjustment). Caution as increased risk of bleeding, especially with body weight <45 kg. Consider anti-Xa monitoring.
Increased risk of bleeding; consider lower doses (e.g., 0.5 mg/kg every 12 hours or 1 mg/kg once daily) and monitor renal function
Epidural or spinal hematomas may occur in patients anticoagulated with low molecular weight heparins or heparinoids who receive neuraxial anesthesia or undergo spinal puncture. These hematomas may result in long-term or permanent paralysis. Consider monitoring for signs and symptoms of neurological impairment and urgent treatment if suspected.
Enoxaparin carries a black box warning for the risk of spinal or epidural hematomas in patients receiving neuraxial anesthesia or spinal puncture, which can result in long-term or permanent paralysis. Patients should be monitored for signs of neurological impairment, and concomitant use of drugs affecting hemostasis (e.g., NSAIDs, antiplatelet agents, other anticoagulants) increases the risk.
Risk of hemorrhage: monitor for signs of bleeding,Thrombocytopenia: risk of heparin-induced thrombocytopenia (HIT),Use with caution in patients with renal impairment (creatinine clearance <30 m L/min) as exposure may be increased,Do not administer intramuscularly due to risk of hematoma,Monitor anti-factor Xa activity in patients with severe renal impairment, obesity, or during pregnancy
Spinal/epidural hematoma risk with neuraxial anesthesia,Increased bleeding risk, especially in patients with renal impairment, thrombocytopenia, or age >65,Heparin-induced thrombocytopenia (HIT) risk; monitor platelet counts regularly,Use with caution in patients with severe renal impairment (Cr Cl <30 m L/min), as enoxaparin accumulates and increases bleeding risk; dose adjustment required,Not recommended in patients with mechanical heart valves, especially pregnant women, due to risk of valve thrombosis,Do not mix with other injections or infusions
History of heparin-induced thrombocytopenia (HIT) or heparin-induced thrombocytopenia with thrombosis (HITT),Active major bleeding,Known hypersensitivity to tinzaparin, heparin, or pork products,Concurrent use of neuraxial anesthesia or spinal puncture (relative; requires caution),Severe uncontrolled hypertension
Active major bleeding or bleeding disorders (e.g., hemophilia, thrombocytopenic purpura),History of heparin-induced thrombocytopenia (HIT) or heparin-induced thrombocytopenia and thrombosis (HITT),Hypersensitivity to enoxaparin, heparin, or pork products,Not recommended for use in patients with mechanical heart valves (especially pregnant women) due to risk of valve thrombosis,Concomitant use of other drugs that significantly increase bleeding risk (e.g., warfarin, aspirin, clopidogrel) without careful monitoring and indication
No specific food interactions. Avoid excessive consumption of vitamin K-rich foods (e.g., leafy greens) if also on warfarin; not required with Innohep alone. Limit alcohol intake as it may increase bleeding risk.
No specific food interactions. However, foods high in vitamin K (e.g., leafy greens) may theoretically affect coagulation but are not clinically significant with enoxaparin. Avoid excessive alcohol intake due to potential bleeding risk. Maintain consistent diet if also taking warfarin.
Innohep (tinzaparin) is a low molecular weight heparin. No evidence of teratogenicity in animal studies. Human data limited; risk of fetal hemorrhage or teratogenicity is low. Use during pregnancy only if clearly needed. First trimester: minimal risk. Second and third trimesters: increased risk of bleeding, but no structural teratogenic effects reported.
Enoxaparin sodium does not cross the placenta and is not associated with teratogenicity in humans. However, there is a risk of hemorrhage during delivery. Use during pregnancy requires careful monitoring for bleeding.
Tinzaparin is not excreted into breast milk in significant amounts due to high molecular weight. M/P ratio not established; expected to be low. Considered compatible with breastfeeding by most authorities.
Excretion into breast milk is minimal; M/P ratio not determined. Considered compatible with breastfeeding; no known adverse effects in nursing infants, but monitor for bleeding signs.
Pregnancy may require dose adjustments due to increased plasma volume and renal clearance. Monitor anti-Xa levels if needed; adjust dose to maintain therapeutic range. No standard dosing algorithm; individualize based on weight and renal function.
Pregnancy increases volume of distribution and clearance of enoxaparin, necessitating dose adjustment. Monitor anti-Xa levels and adjust dose to maintain target levels, typically requiring higher doses per weight in late pregnancy.
Use anti-Xa monitoring in patients with renal impairment (Cr Cl <30 m L/min) or extremes of body weight. Innohep (tinzaparin) has a higher molecular weight than other LMWHs, leading to a longer half-life and potential for accumulation in renal failure. Avoid in patients with heparin-induced thrombocytopenia (HIT) history. Protamine sulfate partially reverses effect (up to 60%). Monitor platelets periodically due to risk of HIT.
Enoxaparin is a low molecular weight heparin (LMWH) that preferentially inhibits factor Xa over thrombin. Monitor anti-Xa levels in patients with renal impairment (Cr Cl <30 m L/min), obesity, or pregnancy. Avoid intramuscular injections and use with caution in patients receiving neuraxial anesthesia due to risk of spinal hematoma. Protamine sulfate partially reverses enoxaparin (up to 60% of anti-Xa activity). Does not routinely require monitoring of a PTT.
Do not stop or change dose without consulting your doctor.,Report any signs of unusual bleeding or bruising, black/tarry stools, or blood in urine.,Avoid aspirin, NSAIDs, or other blood thinners unless prescribed.,Use electric razor and soft toothbrush to minimize bleeding risk.,Seek immediate medical help if you experience severe headache, vision changes, or signs of allergic reaction.,Do not rub injection site; rotate sites (abdomen, thigh, upper arm).,Keep a record of injection dates and times.
Inject subcutaneously as directed, rotating injection sites (e.g., left/right abdomen, alternating).,Do not massage the injection site after administration.,Report any signs of bleeding: unusual bruising, prolonged bleeding from cuts, blood in urine or stool, coughing up blood.,Seek immediate medical attention for symptoms of spinal hematoma after neuraxial procedure: back pain, numbness or weakness in legs, bowel/bladder dysfunction.,Inform all healthcare providers (including dentists) that you are taking enoxaparin.,Avoid NSAIDs, aspirin, or other blood thinners unless prescribed by your doctor.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about INNOHEP vs ENOXAPARIN SODIUM, answered by our medical review team.
INNOHEP is a Low Molecular Weight Heparin that works by Tinzaparin is a low molecular weight heparin that binds to antithrombin III, accelerating its inhibition of factor Xa and thrombin (factor IIa), thereby exerting anticoagulant effects.. ENOXAPARIN SODIUM is a Low Molecular Weight Heparin that works by Enoxaparin binds to antithrombin III (ATIII) via its pentasaccharide sequence, enhancing ATIII-mediated inhibition of factor Xa and, to a lesser extent, factor IIa (thrombin). It preferentially inhibits factor Xa over thrombin (anti-Xa:anti-IIa ratio ~3.6:1).. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between INNOHEP and ENOXAPARIN SODIUM depend on the specific clinical indication. These are both Low Molecular Weight Heparin agents and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of INNOHEP is: Subcutaneous administration: 2500 IU anti-Xa (0.25 m L) once daily for low to moderate risk of thromboembolism; 3500 IU anti-Xa (0.35 m L) once daily for high risk. For treatment of deep vein thrombosis (DVT): 175 IU anti-Xa/kg body weight once daily by subcutaneous injection. Maximum dose: 17,500 IU per day.. The standard adult dose of ENOXAPARIN SODIUM is: 1 mg/kg subcutaneous every 12 hours or 1.5 mg/kg subcutaneous once daily. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between INNOHEP and ENOXAPARIN SODIUM in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. INNOHEP is classified as Category C. Innohep (tinzaparin) is a low molecular weight heparin. No evidence of teratogenicity in animal studies. Human data limited; risk of fetal hemorrhage or teratogenicity is low. Use . ENOXAPARIN SODIUM is classified as Category A/B. Enoxaparin sodium does not cross the placenta and is not associated with teratogenicity in humans. However, there is a risk of hemorrhage during delivery. Use during pregnancy requ. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.